Antimicrobial stewardship in the intensive care unit: A focus on potential pitfalls

Journal of Pharmacy Practice

Volumn 23, Issue 1, 2010, Pages 50-60

  Njoku, Jessica C ^a,b   Hermsen, Elizabeth D ^a,b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antimicrobial resistance; Antimicrobial stewardship; Intensive care unit; Nosocomial infections

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; FLUCONAZOLE; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULPERAZON; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BACTERIAL PERITONITIS; COST OF ILLNESS; DRUG APPROVAL; DRUG FORMULARY; DRUG MISUSE; DRUG USE; DRUG UTILIZATION; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; GONORRHEA; HEALTH PROGRAM; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFORMATION TECHNOLOGY; INTENSIVE CARE UNIT; KLEBSIELLA INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PSEUDOMONAS INFECTION; REVIEW; SURGICAL INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 77949393314     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009356554     Document Type: Review

References (69)

1. IDSA. Strategies to Address Antimicrobial Resistance (STAAR) Act. http://www.idsociety.org/STAARAct.htm. Accessed July 20, 2009.
2. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2): 159-177.
3. Owens RC Jr. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn Microbiol Infect Dis. 2008;61(1):110-128.
4. Chandrasekar PH, Kruse JA, Mathews MF. Nosocomial infection among patients in different types of intensive care units at a city hospital. Crit Care Med. 1986;14(5):508-510.
5. Weber DJ, Raasch R, Rutala WA. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest. 1999;115(3 suppl):34S-41S.
6. Jones ME, Draghi DC, Thornsberry C, et al. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob. 2004;3:14.
7. Karam GH, Heffner JE. Emerging issues in antibiotic resistance in blood-borne infections. Am J Respir Crit Care Med. 2000;162(5): 1610-1616.
8. CDC. Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. http://www.cdc.gov/drugresistance/healthcare/problem.htm. Accessed July 20, 2009.
9. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470-485.
10. Rehm SJ, Bartlett JG. Challenges in the management of serious infections. Clin Infect Dis. 2006;42(suppl 2):S63-S64.
11. Volles DF, Branan TN. Antibiotics in the intensive care unit: focus on agents for resistant pathogens. Emerg Med Clin North Am. 2008;26(3):813-834, x.
12. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.
13. Madani N, Rosenthal VD, Dendane T, et al. Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: findings of the International Nosocomial Infection Control Consortium (INICC). Int Arch Med. 2009;2(1):29.
14. Owens RC Jr, Fraser GL, Stogsdill P. Antimicrobial stewardship programs as a means to optimize antimicrobial use. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2004;24(7):896-908.
15. Rosenthal VD, Maki DG, Mehta A, et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control. 2008;36(9):627-637.
16. Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002;162(19):2223-2228.
17. Carmeli Y, Troillet N, Karchmer AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999;159(10):1127-1132.
18. Cosgrove SE, Kaye KS, Eliopoulous GM, et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162(2): 185-190.
19. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillinsusceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53-59.
20. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36(5):592-598.
21. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(suppl 2):S82-S89.
22. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med. 2009;179(6):434-438.
23. Levy SB. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother. 2002;49(1):25-30.
24. Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med. 2008;121(4): 310-315.
25. Johnson JK, Smith G, Lee MS, et al. The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit. J Infect Dis. 2009;200(6):900-905.
26. Erbay A, Colpan A, Bodur H, et al. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int J Antimicrob Agents. 2003;21(4):308-312.
27. Gonzales R, Malone DC, Maselli JH, et al. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33(6):757-762.
28. John JF. Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24(3):471-485.
29. Erlandsson M, Burman LG, Cars O, et al. Prescription of antibiotic agents in Swedish intensive care units is empiric and precise. Scand J Infect Dis. 2007;39(1):63-69.
30. Warren MM, Gibb AP, Walsh TS. Antibiotic prescription practice in an intensive care unit using twice-weekly collection of screening specimens: a prospective audit in a large UK teaching hospital. J Hosp Infect. 2005;59(2):90-95.
31. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996;22(5):387-394.
32. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118(1): 146-155.
33. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-474.
34. Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38(9):1279-1286.
35. Centers for Medicare and Medicaid Services. QualityNet. http:// www.qualitynet.org. Accessed August 20, 2009.
36. Hermsen ED, Smith Shull S, Puumala SE, et al. Improvement in prescribing habits and economic outcomes associated with the introduction of a standardized approach for surgical antimicrobial prophylaxis. Infect Control Hosp Epidemiol. 2008;29(5): 457-461.
37. Ansari F, Gray K, Nathwani D, et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother. 2003;52(5):842-848.
38. Carling P, Fung T, Killion A, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24(9):699-706.
39. LaRocco A. Concurrent antibiotic review programs-a role for infectious diseases specialists at small community hospitals. Clin Infect Dis. 2003;37(5):742-743.
40. Ruttimann S, Keck B, Hartmeier C, et al. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis. 2004;38(3):348-356.
41. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycinresistant enterococci. Clin Infect Dis. 1996;23(5):1020-1025.
42. Bradley SJ, Wilson AL, Allen MC, et al. The control of hyperendemic glycopeptide-resistant Enterococcus spp. On a haematology unit by changing antibiotic usage. J Antimicrob Chemother. 1999;43(2):261-266.
43. Dahms RA, Johnson EM, Statz CL, et al. Third-generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant enterococcus infection. Arch Surg. 1998;133(12):1343-1346.
44. Tornieporth NG, Roberts RB, John J, et al. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis. 1996;23(4):767-772.
45. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280(14):1233-1237.
46. Martin C, Ofotokun I, Rapp R, et al. Results of an antimicrobial control program at a university hospital. Am J Health Syst Pharm. 2005;62(7):732-738.
47. Gentry CA, Greenfield RA, Slater LN, et al. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm. 2000;57(3):268-274.
48. Ng CK, Wu TC, Chan WM, et al. Clinical and economic impact of an antibiotics stewardship programme in a regional hospital in Hong Kong. Qual Saf Health Care. 2008;17(5):387-392.
49. Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, bacterial resistance. Clin Infect Dis. 2003;37(2):180-186.
50. Fraser GL, Stogsdill P, Dickens JD Jr, et al. Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med. 1997;157(15):1689-1694.
51. Gross R, Morgan AS, Kinky DE, et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001;33(3):289-295.
52. Srinivasan A, Song X, Richards A, et al. A survey of knowledge, attitudes, beliefs of house staff physicians from various specialties concerning antimicrobial use and resistance. Arch Intern Med. 2004;164(13):1451-1456.
53. Sunenshine RH, Liedtke LA, Jernigan DB, et al. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis. 2004;38(7):934-938.
54. Fitzpatrick F, Roche F, Cunney R, et al. Challenges of implementing national guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus colonization or infection in acute care hospitals in the Republic of Ireland. Infect Control Hosp Epidemiol. 2009;30(3):277-281.
55. White AC. Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, clinical outcomes. Clin Infect Dis. 1997;25(2):230-239.
56. Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter? Crit Care. 2009;13(3):214.
57. Endimiani A, Paterson DL. Optimizing therapy for infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Semin Respir Crit Care Med. 2007;28(6): 646-655.
58. Kasiakou SK, Lawrence KR, Choulis N, et al. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs. 2005;65(17): 2499-2511.
59. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655.
60. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44(1):79-86.
61. Angus BJ, Smith MD, Suputtamongkol Y, et al. Pharmacokineticpharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol. 2000;50(2):184-191.
62. Benko AS, Cappelletty DM, Kruse JA, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother. 1996;40(3):691-695.
63. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther. 2000;22(1):66-75.
64. Feld R, Rachlis A, Tuffnell PG, et al. Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Arch Intern Med. 1984;144(5):1005-1010.
65. Lodise TP. Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357-363.
66. Young RJ, Lipman J, Gin T, et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother. 1997;40(2):269-273.
67. Hota S, Hirji Z, Stockton K, et al. Outbreak of multidrug-resistant Pseudomonas aeruginosa colonization and infection secondary to imperfect intensive care unit room design. Infect Control Hosp Epidemiol. 2009;30(1):25-33.
68. Chang HL, Tang CH, Hsu YM, et al. Nosocomial outbreak of infection with multidrug-resistant Acinetobacter baumannii in a medical center in Taiwan. Infect Control Hosp Epidemiol. 2009;30(1):34-38.
69. Carling PC, Von Beheren S, Kim P, et al. Intensive care unit environmental cleaning: an evaluation in sixteen hospitals using a novel assessment tool. J Hosp Infect. 2008;68(1):39-44.